Immune microenvironment, homologous recombination deficiency, and therapeutic response to neoadjuvant chemotherapy in triple-negative breast cancer: Japan Breast Cancer Research Group (JBCRG)22 TR
Takayuki Ueno(Doshisha Women's College of Liberal Arts), Masakazu Toi(Kyoto University)
Cited by 19
Related Papers
Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies
|British Journal of Cancer|2009|94
Prognostic significance of tumor/stromal caveolin‐1 expression in breast cancer patients
|Cancer Science|2011|62
Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil–epirubicin–cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuvant chemotherapy
|Breast Cancer Research and Treatment|2013|55
Paradigm Shift toward Reducing Overtreatment of Ductal Carcinoma In Situ of Breast
|Frontiers in Oncology|2017|29